OncLive

RYZ101 Meets Primary PFS End Point in Phase 3 ACTION-1 Trial for Post–Lutetium-177 GEP-NETs

October 12, 2026

The source didn’t give us enough text to summarize this story. Use “Read original source” above to read it at OncLive.

Want more like this?

Browse more from the feed. A free account unlocks the full feed, saving and communities.